Skip to main content

Table 2 Seven-point ordinal categorical primary endpoint of the CLARITY trial

From: Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

Category Description
1 Not hospitalised with no limitation on activities
2 Not hospitalised with some limitation on activities
3 Hospitalised, not requiring supplemental oxygen
4 Hospitalised, requiring supplemental oxygen
5 Hospitalised, requiring non-invasive mechanical ventilation or high-flow nasal cannular (HFNC) therapy
6 Hospitalised, requiring mechanical ventilation ± additional organ support
7 Died